AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17548839 — intervention group
Group type: COMPARATOR
Intervention: FUOX (continuous‐infusion FU 2,250 mg/m2 during 48 hours on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m2 on days 1, 15, and 29 every 6 weeks)
Number of subjects: 348
Study 17548839 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 348
Study 17548839 — intervention group
Group type: COMPARATOR
Intervention: FUOX
Number of subjects: 348
Study 15157039 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 61
Study 15157039 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 61
Study 11322176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily for 4 days
Number of subjects: 8
Study 11322176 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 8
Study 11322176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9478089 — intervention group
Group type: COMPARATOR
Intervention: Maximal inspiratory pressures in males
Number of subjects: 54
Study 9478089 — intervention group
Group type: COMPARATOR
Intervention: Maximal inspiratory pressures in females
Number of subjects: 54
Study 9478089 — intervention group
Group type: COMPARATOR
Intervention: Maximal expiratory pressures in males
Number of subjects: 54
Study 9478089 — intervention group
Group type: COMPARATOR
Intervention: Maximal expiratory pressures in females
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished peak expiratory flow in females
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished peak expiratory flow in males
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bronchitis diagnosis
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive impairment of pulmonary function
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between decreased PEF and MEP in males
Number of subjects: 54
Study 9478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between decreased PEF and MEP in females
Number of subjects: 54
Study 7943103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion (600 ml saline solution bolus followed by 3 ml/min)
Number of subjects: 93
Study 7943103 — intervention group
Group type: COMPARATOR
Intervention: Standard care (including therapeutic amnioinfusion for variable decelerations)
Number of subjects: 93
Study 7943103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 93
Study 7943103 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 93
Study 3307517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.01 mg/kg atropine sulphate
Number of subjects: 40
Study 3307517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atropine)
Number of subjects: 40
Study 31338923 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 81
Study 31338923 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (galactooligosaccharide)
Number of subjects: 81
Study 31338923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29157872 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 0
Study 29157872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28539142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 17
Study 28539142 — intervention group
Group type: COMPARATOR
Intervention: Sham inspiratory muscle training
Number of subjects: 17
Study 26154547 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened fasting with maltodextrin intake 2 hours before surgery
Number of subjects: 92
Study 23846759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 67
Study 23846759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21704238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg (test formulation)
Number of subjects: 24
Study 21704238 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg (reference formulation)
Number of subjects: 24
Study 21704238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 19319953 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg dose of inactivated influenza vaccine
Number of subjects: 815
Study 19319953 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg dose of inactivated influenza vaccine
Number of subjects: 815
Study 19319953 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg dose followed by 15 microg booster
Number of subjects: 815
Study 19319953 — intervention group
Group type: COMPARATOR
Intervention: 15 microg dose followed by placebo
Number of subjects: 815
Study 19319953 — intervention group
Group type: COMPARATOR
Intervention: 30 microg dose followed by placebo
Number of subjects: 815
Study 17047401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen withdrawal
Number of subjects: 190
Study 12767538 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 54
Study 10838460 — intervention group
Group type: EXPERIMENTAL
Intervention: New human milk fortifier
Number of subjects: 29
Study 10838460 — intervention group
Group type: COMPARATOR
Intervention: Reference human milk fortifier
Number of subjects: 29
Study 9021380 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly depot leuprolide
Number of subjects: 30
Study 9021380 — intervention group
Group type: COMPARATOR
Intervention: Monthly depot leuprolide
Number of subjects: 30
Study 1425865 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 10 mg
Number of subjects: 8
Study 1425865 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 20 mg
Number of subjects: 8
Study 1425865 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 8
Study 1425865 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (all doses) after 7 days
Number of subjects: 8
Study 1425865 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole cessation
Number of subjects: 8
Study 1425865 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretrial smoking (Experiment I)
Number of subjects: 94
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial smoking (Experiment I)
Number of subjects: 94
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretrial smoking (Experiment II)
Number of subjects: 94
Study 6438679 — intervention group
Group type: COMPARATOR
Intervention: Posttrial smoking intervals (1, 5, and 30 min after presentation of a 20-word list) (Experiment II)
Number of subjects: 94
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette (1.38 mg) (Experiment III)
Number of subjects: 94
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette (0.40 mg) (Experiment III)
Number of subjects: 94
Study 6438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (Experiment IV)
Number of subjects: 94
Study 30894213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of haploidentical natural killer (NK) cells
Number of subjects: 21
Study 30894213 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 21
Study 27889883 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin:chymotrypsin (TC)
Number of subjects: 75
Study 27889883 — intervention group
Group type: COMPARATOR
Intervention: Serratiopeptidase (S)
Number of subjects: 75
Study 27889883 — intervention group
Group type: COMPARATOR
Intervention: Trypsin:bromelain:rutoside (TBR)
Number of subjects: 75
Study 27213441 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet (synthetic liquid diet with 30% fewer calories and 80% less protein for five consecutive days)
Number of subjects: 68
Study 27213441 — intervention group
Group type: EXPERIMENTAL
Intervention: DER-diet (synthetic diet containing daily energy requirements)
Number of subjects: 68
Study 27213441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 24465514 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in Heaven
Number of subjects: 0
Study 24465514 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in Hell
Number of subjects: 0
Study 24465514 — intervention group
Group type: COMPARATOR
Intervention: Experimental priming of Hell beliefs
Number of subjects: 0
Study 22360366 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (group II)
Number of subjects: 60
Study 22360366 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% proanthocyanidin (group III)
Number of subjects: 60
Study 22360366 — intervention group
Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 60
Study 19678777 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional water
Number of subjects: 15
Study 19678777 — intervention group
Group type: COMPARATOR
Intervention: Control mineral water
Number of subjects: 15
Study 17474991 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 11 vitamins and 5 minerals for 12 months
Number of subjects: 910
Study 17474991 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet taken daily for 12 months
Number of subjects: 910
Study 15052846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment consisting of postisometric relaxation, massage of the prostate, and transrectal mobilization of the pelvic ligaments
Number of subjects: 106
Study 11344184 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Saizen, Serono, Switzerland) 0.09 IU/kg body weight (BW) 3 times weekly with dietary intervention
Number of subjects: 19
Study 9700978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 12
Study 9700978 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 12
Study 9700978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8016771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 10
Study 8016771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2736877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group (one-quarter of glucose energy replaced by intravenous fat)
Number of subjects: 28
Study 2736877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group
Number of subjects: 28
Study 2736877 — intervention group
Group type: COMPARATOR
Intervention: Glucose/amino acid group
Number of subjects: 28
Study 2736877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 2736877 — intervention group
Group type: COMPARATOR
Intervention: Glucose-only group
Number of subjects: 28
Study 56094 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (n = 11)
Number of subjects: 29
Study 56094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (n = 10)
Number of subjects: 29
Study 56094 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (n = 8)
Number of subjects: 29
Study 31550819 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for gastric GISTs
Number of subjects: 0
Study 31550819 — intervention group
Group type: COMPARATOR
Intervention: Open surgery for colorectal GISTs
Number of subjects: 0
Study 31550819 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for rectal GISTs
Number of subjects: 0
Study 31550819 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of GIST
Number of subjects: 0
Study 28365238 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Carboplatin with Necitumumab
Number of subjects: 167
Study 28365238 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Carboplatin alone
Number of subjects: 167
Study 25919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT) - rabeprazole-amoxicillin-clarithromycin-metronidazole for 14 days; n=122
Number of subjects: 475
Study 25919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (QT) - rabeprazole-tetracycline-metronidazole-colloidal bismuth subcitrate for 10 days; n=97
Number of subjects: 475
Study 25919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-based therapy (LT) - rabeprazole-amoxicillin-levofloxacin for 10 days; n=87
Number of subjects: 475
Study 25919773 — intervention group
Group type: COMPARATOR
Intervention: Non-filling group (control)
Number of subjects: 475
Study 23731454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1072 nm infrared light therapy
Number of subjects: 87
Study 23731454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) light therapy
Number of subjects: 87
Study 22085317 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote support only
Number of subjects: 415
Study 22085317 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person support
Number of subjects: 415
Study 22085317 — intervention group
Group type: COMPARATOR
Intervention: Control (self-directed weight loss)
Number of subjects: 415
Study 19372480 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquid gastric emptying study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid), 30-min duration
Number of subjects: 101
Study 19372480 — intervention group
Group type: COMPARATOR
Intervention: Solid gastric emptying study (standardized 4-h solid-meal study with (99m)Tc-sulfur colloid-labeled egg-substitute sandwich meal)
Number of subjects: 101
Study 19372480 — intervention group
Group type: COMPARATOR
Intervention: Normal solid emptying
Number of subjects: 101
Study 16427165 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable ankles during v-cut movement
Number of subjects: 32
Study 16427165 — intervention group
Group type: COMPARATOR
Intervention: Controls during v-cut movement
Number of subjects: 32
Study 16427165 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable ankles during lateral shuffling
Number of subjects: 32
Study 16427165 — intervention group
Group type: COMPARATOR
Intervention: Controls during lateral shuffling
Number of subjects: 32
Study 12611746 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 28
Study 12611746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10883416 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP 579 (50 micrograms/kg as a 6-hour constant-rate intravenous infusion)
Number of subjects: 0
Study 9332892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl
Number of subjects: 327
Study 9332892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 8457937 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI)
Number of subjects: 123
Study 8457937 — intervention group
Group type: COMPARATOR
Intervention: Small-group review
Number of subjects: 123
Study 3782621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 3782621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 3782621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methylphenidate and cognitive therapy
Number of subjects: 0
Study 3782621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication during post‐testing)
Number of subjects: 0
Study 30840639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes described as "organic"
Number of subjects: 1101
Study 30840639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes described as "natural"
Number of subjects: 1101
Study 30840639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes described as "additive-free"
Number of subjects: 1101
Study 30840639 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes described as "ultra-light"
Number of subjects: 1101
Study 30840639 — intervention group
Group type: EXPERIMENTAL
Intervention: All four types of cigarettes ("organic," "natural," "additive-free," and "ultra-light")
Number of subjects: 1101
Study 29298257 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior change counseling
Number of subjects: 122
Study 29298257 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 27033686 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-to-breath (ATB) meditation
Number of subjects: 26
Study 24947950 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg I/V metronidazole and 1 g Ceftriaxone I/V before induction of anesthesia
Number of subjects: 100
Study 24947950 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 100
Study 22118795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular imaging performed in 61 patients
Number of subjects: 113
Study 19087155 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1-10 ng twice a week)
Number of subjects: 100
Study 19087155 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A (50 U, one injection cycle)
Number of subjects: 100
Study 17355457 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA combined with arterial occlusion (group A)
Number of subjects: 20
Study 17355457 — intervention group
Group type: COMPARATOR
Intervention: RFA alone (group B)
Number of subjects: 20
Study 12548308 — intervention group
Group type: EXPERIMENTAL
Intervention: PABA15 (80 mg at 08:00, 12:00, and 15:00)
Number of subjects: 99
Study 12548308 — intervention group
Group type: EXPERIMENTAL
Intervention: PABA18 (80 mg at 08:00, 12:00, and 18:00)
Number of subjects: 99
Study 12548308 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dosage of 80 mg PABA
Number of subjects: 99
Study 12548308 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg PABA at recommended hours
Number of subjects: 99
Study 12548308 — intervention group
Group type: COMPARATOR
Intervention: Recommended dosage schedule (PABA taken with main meals)
Number of subjects: 99
Study 10700656 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment for 6 weeks
Number of subjects: 24
Study 10700656 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified how many)
Number of subjects: 24
Study 9568324 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin: chymotrypsin preparation
Number of subjects: 0
Study 9568324 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 8446846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 229
Study 8446846 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 229
Study 3017804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (1 g daily enema)
Number of subjects: 24
Study 3017804 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (25 mg daily enema)
Number of subjects: 24
Study 3017804 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 24
Study 31898198 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 40
Study 31898198 — intervention group
Group type: COMPARATOR
Intervention: Sitting group
Number of subjects: 40
Study 30097359 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg risankizumab
Number of subjects: 997
Study 30097359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study 30097359 — intervention group
Group type: COMPARATOR
Intervention: 45 mg or 90 mg ustekinumab
Number of subjects: 997
Study 27637589 — intervention group
Group type: EXPERIMENTAL
Intervention: Single prolonged maximum voluntary contractions (MVCs)
Number of subjects: 9
Study 27637589 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated short maximum voluntary contractions (MVCs)
Number of subjects: 9
Study 27637589 — intervention group
Group type: EXPERIMENTAL
Intervention: Single all-out cycling bouts
Number of subjects: 9
Study 27637589 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated all-out cycling bouts
Number of subjects: 9
Study 27637589 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated drop jumps
Number of subjects: 9
Study 24687506 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI) 560 mg
Number of subjects: 0
Study 24687506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21962978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 or 2 mA for 20 minutes/day for 2 weeks)
Number of subjects: 22
Study 21962978 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS (sham stimulation for 2 weeks)
Number of subjects: 22
Study 21962978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 22
Study 21962978 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 22
Study 21144224 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-infused carboxymethylcellulose (CMC) foam, 4 mL hydrated with triamcinolone, 40 mg/mL (Kenalog 40)
Number of subjects: 8
Study 18506677 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent computer game (Unreal Tournament) with VR device
Number of subjects: 148
Study 18506677 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent computer game (Unreal Tournament) without VR device
Number of subjects: 148
Study 18506677 — intervention group
Group type: COMPARATOR
Intervention: Non-violent game (Motocross Madness) with VR device
Number of subjects: 148
Study 18506677 — intervention group
Group type: COMPARATOR
Intervention: Non-violent game (Motocross Madness) without VR device
Number of subjects: 148
Study 16430197 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at baseline (Group 1)
Number of subjects: 28
Study 16430197 — intervention group
Group type: COMPARATOR
Intervention: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at week 24 (Group 2)
Number of subjects: 28
Study 12856476 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left hemispheric lesion
Number of subjects: 17